mcr84

mcr84 is a **monoclonal antibody** that specifically targets vascular endothelial growth factor (VEGF), inhibiting its action by blocking VEGF from binding to its main functional receptor, VEGFR2. By antagonizing VEGFR2-mediated signaling, mcr84 effectively suppresses angiogenesis in tumors, leading to normalization of tumor vasculature, reduction of immune suppression in the tumor microenvironment, and enhanced anti-tumor immune responses. Its activity reduces PD-L1 expression on myeloid-derived suppressor cells (MDSCs), limits their immunosuppressive activity, and enhances both CD8+ T cell activity and cytotoxicity, while inhibiting regulatory T cell (Treg) infiltration. mcr84 is used as a research or preclinical tool to study VEGF/VEGFR2 blockade in cancer models, though it is not an approved human therapeutic or in late-stage human clinical trials[1][3][7][9].